Form 4: Gilead CFO Andrew Dickinson Executes Stock Sale

Gilead Sciences CFO Andrew D. Dickinson sold 3,000 shares of common stock under a pre-established Rule 10b5-1 trading plan.

Summary

• Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences, Inc., sold 3,000 shares of common stock.
• The transaction occurred on June 15, 2026, at a price of $125.40 per share.
• Following this transaction, the reporting person maintains beneficial ownership of 171,646 shares of Gilead common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted under a pre-arranged plan and represents a minor portion of the executive's total holdings.

Positives

• The transaction was pre-planned under a Rule 10b5-1 plan, indicating the sale was not based on non-public information or short-term market sentiment.

Negatives

• The sale represents a reduction in the direct equity stake held by a key executive.

Risks

• Executive stock sales can sometimes be perceived negatively by retail investors as a lack of confidence in future share price appreciation.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that executive stock sales under 10b5-1 plans are standard corporate practice for liquidity and diversification, and generally do not signal a change in company fundamentals.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to sell shares while avoiding potential insider trading liability.
• The volume of shares sold (3,000) is relatively small compared to the total holdings (171,646), representing less than 2% of the executive's position.

Stakeholder Impact

• Minimal impact expected on shareholders as the sale was pre-planned and represents a small fraction of the executive's total ownership.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Gilead Sciences, GILD, Insider Trading, Form 4, CFO, Stock Sale